Kevin Ballinger has been appointed to Silk Road Medical’s board of directors.  Simultaneously, the company also announced the resignation of a current board member, Ruoxi Chen. Both of these changes are effective immediately.

The company is focused on reducing the risk of stroke and its devastating impact.

Kevin Ballinger, the recently appointed Chief Executive Officer of Aldevron, brings decades of experience in the medical device industry. Prior to joining Aldevron, he spent 25 years at Boston Scientific, a company focused on a variety of interventional medical specialties. During his last nine years at Boston Scientific, he served as Executive Vice President and Global President of the Interventional Cardiology division. Under his leadership, Ballinger grew the division to a $3 billion global business. Ballinger earned his BS in Mechanical Engineering from Michigan Technological University and his MBA from the University of Minnesota’s Carlson School of Management.

“We are delighted to welcome Kevin to our Board of Directors. Kevin brings extensive strategic leadership experience in the medical device industry, with a proven track record of successfully building and growing businesses,” said Erica Rogers, Chief Executive Officer. “His guidance will be instrumental as we look toward significant growth and operational expansion at Silk Road Medical.”

“Silk Road Medical has established itself as a leader in the treatment of carotid artery disease with its revolutionary transcarotid access and neuroprotection products,” said Ballinger. “I am excited about the future prospects of the company and look forward to working together as we continue to build a world-class organization. I am thrilled to be joining such a dedicated team that is at the forefront of innovation.”